Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 172 clinical trials
In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer

weeks of treatment with platinum-based chemotherapy and (2) who have signed consent to participate in a clinical trial that contains PARP inhibitor therapy and are anticipated to receive this treatment

adenocarcinoma
breast ductal carcinoma
pancreatic adenocarcinoma
ct scan
cancer chemotherapy
  • 8 views
  • 26 Jan, 2021
  • 1 location
A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

other countries for the treatment of patients with unresectable or metastatic melanoma, advanced NSCLC with progression on or after platinum-based chemotherapy, advanced RCC whose disease progressed on

platinum-based chemotherapy
carcinoma
carboplatin
paclitaxel
squamous cell carcinoma
  • 0 views
  • 23 Jan, 2021
BEACON - ABC in Recurrent Platinum Resistant HGSOC

> The majority of women diagnosed with High Grade Serous Ovarian Cancer present with advanced disease, and are typically managed with a combination of cytoreductive surgery and platinum-based

ovarian epithelial carcinoma
bevacizumab
cancer
platinum-based chemotherapy
atezolizumab
  • 30 views
  • 23 Jan, 2021
  • 1 location
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is envisaged that the combination should improve …

  • 0 views
  • 17 Feb, 2021
  • 4 locations
Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting

This study aims to evaluate the effects of niraparib in those who have received neoadjuvant chemotherapy and subsequent interval debulking surgery, with or without hyperthermic intraperitoneal chemotherapy, and would also explore if there are any biomarkers, other than BRCA / HRD status and platinum sensitivity, that may help to identify …

primary peritoneal carcinoma
niraparib
platinum-based chemotherapy
carcinoma
carboplatin
  • 0 views
  • 25 Jan, 2021
  • 1 location
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

This is an open-label, prospective, randomized, controlled, parallel group, multi-center phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of platinum-based reinduction therapy and with no clinical benefit.

  • 2 views
  • 24 Jan, 2021
  • 42 locations
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component 20%

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

  • 2 views
  • 21 Jan, 2021
  • 1 location
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for patients with advanced or metastatic non-small cell lung cancer and metastatic triple-negative breast cancer. Part 2 will evaluate the safety, pharmacokinetics and pharmacodynamics, immunogenicity and preliminary evidence of …

breast cancer
lung carcinoma
cancer
platinum-based chemotherapy
triple-negative breast cancer
  • 228 views
  • 19 Feb, 2021
  • 38 locations
Ceritinib Plus Docetaxel in ALK-Negative EGFR WT Advanced NSCLC

The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia) used in combination with docetaxel (Taxotere) will have on participants and their cancer. The results will help to determine the best safe dose of the combination of the medications Ceritinib (Zykadia) and docetaxel …

brain metastases
cancer
docetaxel
leptomeningeal disease
metastasis
  • 8 views
  • 28 Jan, 2021
  • 2 locations
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of IMP4297 for Maintenance Treatment

cancer antigen 125
cancer chemotherapy
peritoneal cancer
carboplatin
cancer of the ovary
  • 12 views
  • 23 Jan, 2021
  • 2 locations